首页 Cerus(usCERS)-基本信息

Cerus(usCERS)-基本信息

日报更新时间:

周报更新时间:04-11 03:39

行情信息

今开价:6.34

最高价:6.39

成交量:1227186.0

昨收价:6.35

最低价:6.09

最新价:6.18

行情图标
概要信息

英文名称:Cerus


行业:医疗


简介:Cerus Corporation于1991年在美国加州成立,并于1996年在特拉华州重新合并成立,该公司是一家生物医药产品公司,专注于“拦截血液系统”的商业化推广,以加强血液安全


电话:1-925-2886000


最新量化综合结论
百科信息
  • 相关网站
  • 百科
  • 员工交易记录
  • 持股信息
  • 领导人信息

Cerus Corporation的INTERCEPT血液系统为基于其专利技术、控制生物学的复制与设计、标靶血液传染病原体,并使其失去活性,包括:病毒,细菌,寄生虫,以及潜在性有害的白血球,同时保留血小板,血浆及红血球治疗特性。Cerus Corporation的INTERCEPT血液系统,用于输血时,利用捐赠血小板,血浆及红血球之方,将设计好的血小板,血浆及红血球,使血液传染病原体失去活性。Cerus Corporation主要通过直销团队及经销商,销售其血小板与血浆系统。此外,Cerus Corporation也与Baxter International, Inc.签订共同研究,开发及商业化INTERCEPT血液系统。

交易日期 交易人 职位 类型 交易份额 价格
2019-06-03 Anderson (Timothy B) Director Buy 10223 --
2019-06-03 Swisher (Daniel N Jr) Director Buy 12758 --
2019-06-03 Schulze (Gail Gaumer) Director Buy 10223 --
2019-06-03 Witney (Franklin R. Ph.D.) Director Buy 10223 --
2019-06-03 Greenman (William Mariner) Chief Executive Officer Buy 10000 4.60
2019-04-21 Greenman (William Mariner) Chief Executive Officer Buy 100 1.06
2019-04-09 Green (Kevin Dennis) Chief Financial Officer Buy 2786 2.15
2019-04-09 Green (Kevin Dennis) Chief Financial Officer Sell 2786 6.51
2019-03-12 Moore (Carol M) Officer Sell 5979 5.90
2019-03-12 Benjamin (Richard J. Ph.D.) Officer Sell 2832 5.90
2019-03-12 Benjamin (Richard J. Ph.D.) Officer Sell 5979 5.90
2019-03-12 Moore (Carol M) Officer Sell 2832 5.90
2019-03-12 Menard (Chrystal N.) Officer Sell 2832 5.90
2019-03-12 Menard (Chrystal N.) Officer Sell 5979 5.90
2019-03-12 Jayaraman Vivek K Officer Sell 5979 5.90
2019-03-12 Greenman (William Mariner) Chief Executive Officer Sell 27059 5.90
2019-03-12 Green (Kevin Dennis) Chief Financial Officer Sell 5979 5.90
2019-03-12 Green (Kevin Dennis) Chief Financial Officer Sell 2832 5.90
2019-03-12 Greenman (William Mariner) Chief Executive Officer Sell 10619 5.90
2019-03-11 Menard (Chrystal N.) Officer Buy 15834 --
2019-03-11 Benjamin (Richard J. Ph.D.) Officer Buy 7500 --
2019-03-11 Green (Kevin Dennis) Chief Financial Officer Sell 2075 6.48
2019-03-11 Greenman (William Mariner) Chief Executive Officer Buy 28125 --
2019-03-11 Jayaraman Vivek K Officer Buy 15834 --
2019-03-11 Greenman (William Mariner) Chief Executive Officer Sell 7781 6.48

机构持股
持有者 持有份额 持股比例 份额变化 变化率 报告日期
BAMCO Inc 1639409 1.19% 319409 24.20% 2019-03-31
Vanguard Investments Australia Ltd 3835434 2.73% -162 -- 2019-07-31
Elk Creek Partners LLC 5740291 4.16% -14941 -0.26% 2019-03-31
BlackRock Fund Advisors 6057284 4.32% 29657 0.49% 2019-07-31
Vanguard Group Inc 6983546 5.07% 311734 4.67% 2019-03-31
ARK Investment Management LLC 7639433 5.54% 898651 13.33% 2019-03-31
Baker Bros Advisors LP 10749937 7.80% -- -- 2019-03-31
BlackRock Inc 10771661 7.81% -22746 -0.21% 2019-03-31
PRIMECAP Management Company 10800000 7.84% -- -- 2019-03-31
State Street Corporation 3361355 2.44% -30107 -0.89% 2019-03-31
Wells Fargo Funds Management LLC 3293380 2.35% 398887 13.78% 2019-07-31
Northern Trust Investments Inc 2662027 1.90% 64101 2.47% 2019-07-31
Fidelity Management & Research Company 2208691 1.57% 76371 3.58% 2019-07-31
Peregrine Capital Management LLC 1934696 1.40% -208629 -9.73% 2019-03-31
RIMA MANAGEMENT, LLC 1787310 1.30% -100000 -5.30% 2019-03-31
SENVEST INTERNATIONAL LLC 1787310 1.30% -100000 -5.30% 2019-03-31
Geode Capital Management, LLC 1679594 1.22% -1352590 -44.61% 2019-03-31
Northern Trust Investments N A 1664548 1.21% 34750 2.13% 2019-03-31
Northern Trust Corp 1664548 1.21% 34750 2.13% 2019-03-31
Kennedy Capital Management Inc 1640286 1.19% 1640286 -- 2019-03-31
BlackRock Asset Management Canada Ltd 3044949 2.21% -977 -0.03% 2019-05-31
Millennium Management LLC 1267355 0.93% 686333 118.13% 2018-12-31
State Street Global Advisors 1228084 0.90% 38600 3.25% 2019-03-31
Ameriprise Financial Inc 1083200 0.79% 1083200 -- 2018-12-31
Driehaus Capital Management LLC 1369940 1.00% 3644 0.27% 2018-09-30
Man Group PLC 1043123 0.77% 560723 116.24% 2018-09-30
SSGA Funds Management Inc 1310008 0.97% 1818 0.14% 2018-11-30
BlackRock Institutional Trust Company NA 3532639 2.60% 348747 10.95% 2018-06-30
TIAA-CREF Investment Management LLC 514874 0.39% 154768 42.98% 2018-06-30
Charles Schwab Investment Management Inc 678414 0.52% 50502 8.04% 2018-06-30
Raymond James & Associates 851895 0.65% 35700 4.37% 2018-06-30
Citadel Advisors Llc 1041025 0.80% -262627 -20.15% 2018-06-30
D. E. Shaw & Co LP 1054900 0.81% 544903 106.84% 2018-06-30
Peregrine Capital Management Inc 2126153 1.64% -714351 -25.15% 2018-03-31
State Street Corp 3172205 2.43% 701434 28.39% 2018-06-30
Medical Strategy GmbH 450448 0.35% -70000 -13.45% 2018-06-30
Essex Investment Management Company, LLC 470797 0.36% 57 0.01% 2018-06-30
DZ BANK AG Deutsche Zentral-Genossenschaftsbank 625016 0.48% 625016 -- 2018-03-31
NN Investment Partners Holdings N.V. 650000 0.50% 150000 30.00% 2018-03-31
NORGES BANK 1032357 0.89% 249222 31.82% 2017-12-31
Delta Lloyd Asset Management NV 650000 0.50% -- -- 2018-03-31
Apo Asset Management GmbH 797716 0.62% -60000 -7.00% 2018-04-30
First Midwest Bank Trust Division 784416 0.68% -293861 -27.25% 2017-12-31
Oppenheim Asset Mgmt Services S.¨¤ r.l. 1281212 1.14% -28000 -2.14% 2017-09-30
Lesa Sroufe & Company Inc 584062 0.52% -11770 -1.98% 2017-09-30
Renaissance Technologies Corp 560214 0.51% 480114 599.39% 2017-09-30
Wells Capital Management Inc. 829637 0.79% -2161670 -72.27% 2017-06-30
Sectoral Asset Management Inc 1000947 0.97% -187 -0.02% 2016-09-30
AllianceBernstein LP 3519232 3.43% -42640 -1.20% 2016-09-30
Hood River Capital Management LLC 1937949 1.89% 49392 2.62% 2016-09-30
Pictet Asset Management SA 1227079 1.19% 1227079 -- 2016-09-30
Stephens Inc 1221208 1.19% -162387 -11.74% 2016-09-30
Cortina Asset Management LLC 1042668 1.02% -90869 -8.02% 2016-09-30
Fidelity Management and Research Company 1040617 1.01% 100000 10.63% 2016-09-30
Pier Capital, LLC 848475 0.83% -48384 -5.39% 2016-09-30
BlackRock, Inc. 5750733 3.00% 24498123 0.10% 1999-11-30
OrbiMed Advisors, LLC 10535000 3.00% 44879100 0.10% 1999-11-30
Baker Bros. Advisors LP 13553275 3.00% 57736952 0.10% 1999-11-30
共同基金持股
持有者 持有份额 持股比例 份额变化 变化率 报告日期
NT R2000 Index Fund - NL 512577 0.37% 4106 0.81% 2019-06-30
PrimeCap Odyssey Aggressive Growth Fund 11300000 8.05% 500000 4.63% 2019-06-30
ARK Innovation ETF 5255206 3.75% -29196 -0.55% 2019-06-30
Vanguard Total Stock Market Index Fund 3807521 2.71% -- -- 2019-06-30
iShares Russell 2000 ETF 2977141 2.12% 5830 0.20% 2019-07-30
Vanguard Extended Market Index Fund 1927646 1.37% 7812 0.41% 2019-06-30
Baron Discovery Fund 1830000 1.30% 190591 11.63% 2019-06-30
Wells Fargo Small Co Gr Port 1660032 1.18% 213920 14.79% 2019-06-30
Wells Fargo Small Company Growth Fund 1633348 1.16% 210186 14.77% 2019-06-30
ARK Genomic Revolution ETF 1448407 1.03% -33408 -2.25% 2019-06-30
iShares Nasdaq Biotechnology ETF 1360650 0.97% 11883 0.88% 2019-07-30
SEB Nordamerikafond Sm 513834 0.37% -8000 -1.53% 2019-06-30
Fidelity 548350 0.39% -1163 -0.21% 2019-04-30
State Street Russell Small Cap 552169 0.39% -- -- 2019-06-30
State Street Russell Small/Mid Cap 568120 0.40% -- -- 2019-06-30
SPDR 1002132 0.71% -- -- 2019-07-31
Harbor Small Cap Growth Opps Fd 1067351 0.76% 174445 19.54% 2019-06-30
iShares Russell 2000 Growth ETF 1107209 0.79% 15753 1.44% 2019-07-30
Wanger USA 619393 0.45% -- -- 2019-05-31
Ivy Small Cap Core Fund 887019 0.64% 283300 46.93% 2019-03-31
iShares US Small Cap ETF (CAD-Hedged) 2756898 2.00% -4626 -0.17% 2019-05-30
ARK Genomic Revolution Multi-Sector ETF 1306680 0.95% 66568 5.37% 2019-04-30
NT R2000 Growth Index Fund - Non-Lending 518717 0.38% -- -- 2019-03-31
MEDICAL BioHealth 498538 0.36% 84000 20.26% 2018-12-31
PNC Multi Factor Small Cap Core 475441 0.35% -7573 -1.57% 2019-01-31
Schwab US Small-Cap ETF 391572 0.29% -- -- 2019-02-27
FCP MEDICAL BioHealth-Trends 448538 0.33% -1910 -0.42% 2018-10-31
Vanguard Health Care Index Fund 352197 0.26% 17101 5.10% 2018-12-31
iShares Micro-Cap ETF 337554 0.25% -- -- 2018-12-31
HeptagonDriehaus US Micro Cap Equity Fd 338755 0.25% 11570 3.54% 2018-10-31
Driehaus Micro Cap Growth Fund 441490 0.33% -25789 -5.52% 2018-10-31
FCP MEDICAL BioHealth 450448 0.33% -70000 -13.45% 2018-06-30
Wells Fargo Small Company Growth Admin 1164650 0.87% -271963 -18.93% 2018-07-31
Schwab Small Cap Index 241200 0.18% -- -- 2018-07-31
Fidelity Spartan 269265 0.20% -- -- 2018-07-31
Vanguard Health Care ETF 279830 0.21% 2394 0.86% 2018-07-31
Northern Trust Russell 2000 Index Fund - DC - Non-Lending 317222 0.24% -984 -0.31% 2018-07-31
PRIMECAP Odyssey Aggressive Growth 10300000 7.89% -- -- 2018-06-30
Vanguard Total Stock Mkt Idx 3386168 2.53% -- -- 2018-07-31
Vanguard Extended Market Idx Inv 1722165 1.29% 32318 1.91% 2018-07-31
iShares Nasdaq Biotechnology 1478090 1.02% -2814 -0.19% 2018-09-12
iShares Russell 2000 Growth 1092976 0.76% -1054 -0.10% 2018-09-12
Harbor Small Cap Growth Opps Instl 931123 0.71% -291993 -23.87% 2018-06-30
Baron Discovery Institutional 801000 0.61% -140000 -14.88% 2018-06-30
Driehaus Micro Cap Growth 465880 0.35% -44911 -8.79% 2018-07-31
CREF Stock R1 357080 0.27% -7234 -1.99% 2018-07-31
iShares Micro-Cap 347947 0.24% -- -- 2018-09-12
PowerShares DWA SmallCap Momentum ETF 220405 0.16% -- -- 2018-08-06
BlackRock Extended Equity Market K 215416 0.17% 75578 54.05% 2018-06-30
The Vanguard Russell 2000 Growth Index 181217 0.14% 1550 0.86% 2018-05-31
Vanguard Instl Ttl Stk Mkt Idx InstlPls 190629 0.15% -- -- 2018-05-31
iShares Russell 2000 Value 171554 0.14% -282 -0.16% 2018-06-21
BlackRock Russell 2000 177050 0.14% 1672 0.95% 2018-03-31
State Street Russell Small/Mid Cap Idx Fd Cl I 351463 0.34% 41471 13.38% 2017-06-30
Optimum Small-Mid Cap Growth A 234499 0.20% 3804 1.65% 2017-12-31
Fidelity Advisor 1040617 1.01% -- -- 2016-10-31
AB Global Thematic Growth A 1082866 1.05% -- -- 2016-12-31
Wells Fargo Emerging Growth Admin 852855 0.82% 18390 2.20% 2016-12-31
Wells Fargo Small Cap Value A 819800 0.79% 88300 12.07% 2016-12-31
VP Partners Small Cap Growth 2 271610 0.26% -232690 -46.14% 2016-12-31
Wells Fargo VT Small Cap Growth 2 270152 0.26% 2330 0.87% 2016-12-31
Royce Smaller-Companies Growth Fund 1347500 1.40% -282000 -17.30% 2015-09-30
Wells Fargo Advantage Small Co Growth 1230600 1.30% -27163 -2.20% 2015-09-30
Wells Fargo Advantage Emerging Gr Fund 947969 1.00% 116394 14.00% 2015-09-30
FCP OP MEDICAL BioHealthTrends 848045 0.90% -- -- 2015-09-30
APO Medical Opportunities 446613 0.50% -- -- 2015-10-31
Triodos Sustainable Pioneer Fund 410000 0.40% -- -- 2015-09-30
Fidelity Spartan® Extended Mkt Indx Fd 380419 0.40% 24653 6.90% 2015-09-30
Vanguard Instl Total Stock Market Index 312316 0.30% -- -- 2015-10-31
iShares Russell 2000 (AU) 1506538 1.60% -1902 -0.10% 2015-11-19

Jami K. Dover Nachtsheim Jami K. Dover Nachtsheim is on the board of Cerus Corp., Intuitive Surgical, Inc. and The Tech Museum of Innovation. Ms. Nachtsheim previously occupied the position of Vice President-Sales & Marketing Group at Intel Corp. and Chairman for Affymetrix, Inc. She received an undergraduate degree from Arizona State University.
Richard J. Benjamin Currently, Richard J. Benjamin holds the position of Chief Medical Officer at Cerus Corp. He is also Director & Director-North America Region at International Society Blood Transfusion and Member of American Association of Blood Banks. Dr. Benjamin previously occupied the position of Chief Medical Officer of American Red Cross, Inc. and Medical Director-Adult Transfusion Service at Harvard University. Dr. Benjamin received a doctorate from the University of Cambridge.
William Mariner Greenman William Mariner Greenman is on the board of Aduro BioTech, Inc. and President, Chief Executive Officer & Director at Cerus Corp. In his past career he was Senior Vice President-Biotech Division at Baxter International, Inc. Mr. Greenman received an undergraduate degree from Stanford University.
Bruce C. Cozadd Mr. Bruce C. Cozadd is Chairman & Chief Executive Officer at Jazz Pharmaceuticals Plc and Chairman & Chief Executive Officer at Jazz Pharmaceuticals, Inc. He is on the Board of Directors at Threshold Pharmaceuticals, Inc., Cerus Corp., Nueva School, Pharmaceutical Research & Manufacturers of America and SFJAZZ. Mr. Cozadd was previously employed as President & Director by Celator Pharmaceuticals, Inc., Chairman & Chief Executive Officer by Azur Pharma Ltd., Chief Operating Officer & Executive Vice President by ALZA Corp., a Member by Harris Upham & Co, Inc., and Member-Health Care Investment Banking Team by Smith Barney Harris Upham & Co., Inc. He also served on the board at Genencor International, Inc. and Stanford Health Care. He received his undergraduate degree from Yale University and an MBA from Stanford Graduate School of Business.
Timothy Bruce Anderson Timothy Bruce Anderson is on the board of Cerus Corp. and Lake Forest Hospital. In his past career he was Senior VP-Strategy & Business Development at Baxter International, Inc.
Franklin R. Witney Dr. Franklin R. Witney is an Independent Director at PerkinElmer, Inc. (United States), an Independent Director at Cerus Corp., a Chairman at Gyros AB, a Chairman at Gyros Protein Technologies AB and a Chief Executive Officer & Director at eBioscience, Inc. He is on the Board of Directors at PerkinElmer, Inc. (United States), Cerus Corp., eBioscience, Inc., Emulate, Inc., GenapSys, Inc., Genoptix, Inc., Nexcelom Bioscience LLC, One Lambda, Inc. and RareCyte, Inc. Dr. Witney was previously employed as a President, Chief Executive Officer & Director by Affymetrix, Inc., a President, Chief Executive Officer & Director by Dionex Corp., a Chief Commercial Officer & Executive VP by Affymetrix, Inc., a President & Chief Executive Officer by Panomics, Inc., a President-Drug Discovery Tools by Nen Life Science Products, Inc., a President by Drug Discovery Facility, a President & Chief Operating Officer by Packard BioScience Co., an Operations Manager-Life Science Group by Bio-Rad Laboratories, Inc., and a President & Chief Executive Officer by GenoSpectra, Inc. He also served on the board at Exagen, Inc., Transgenomic, Inc., Applied Precision LLC and DVS Sciences, Inc. He received his undergraduate degree from the University of Illinois and a doctorate degree from Indiana University.
Eric H. Bjerkholt Founder of Kenady Corp., Eric H. Bjerkholt currently is Chief Financial Officer of Aimmune Therapeutics, Inc. He is also on the board of Cerus Corp. In the past he held the position of President, Chief Executive & Financial Officer at Kenady Corp., President, Chief Executive & Financial Officer at LifeSpring Home Nutrition, CFO, Secretary & EVP-Corporate Development at Sunesis Pharmaceuticals, Inc., Chief Financial Officer & Senior Vice President for IntraBiotics Pharmaceuticals, Inc. and Vice President at J.P. Morgan & Co., Inc. (Delaware). Eric H. Bjerkholt received an undergraduate degree from the University of Oslo and an MBA from Harvard Business School.
Daniel N. Swisher Daniel N. Swisher is Chairman of Cerus Corp. and President & Chief Operating Officer of Jazz Pharmaceuticals Plc. He is also on the board of Corcept Therapeutics, Inc. and The Okizu Foundation. He previously was President, CEO, Secretary & Director at Sunesis Pharmaceuticals, Inc. and Senior Vice President-Sales & Marketing for ALZA Corp. He received an undergraduate degree from Yale University and an MBA from Stanford Graduate School of Business.
Kenneth Trader Currently, Kenneth Trader occupies the position of Vice President-North American Sales at Cerus Corp. He is also on the board of National Hemophilia Foundation. In his past career Mr. Trader held the position of Vice President-Sales & Marketing for Hemophilia Health Services, Inc.
Timothy L. Moore Timothy L. Moore holds the position of Executive Vice President-Technical Operations at Kite Pharma, Inc. He is also on the board of Cerus Corp. and Fusionkite and Member of Parenteral Drug Association and Member of International Society for Pharmaceutical Engineering. In the past Mr. Moore was Vice President-Operations at CSL Behring LLC, Vice President-Operations of Aventis Behring and SVP & Head-Pharmaceutical Technical Operations at Genentech, Inc. Timothy L. Moore received an undergraduate degree from The University of Tulsa and a graduate degree from Northwestern University.
Lori L. Roll Lori L. Roll is Secretary & Vice President-Administration at Cerus Corp.
Gail Gaumer Schulze Gail Gaumer Schulze is on the board of Cerus Corp. In her past career Ms. Schulze was Chairman at ZP Opco, Inc., Chief Executive Officer & Director at YM Biosciences USA, Inc., President, Chief Executive Officer & Director at Eximias Pharmaceutical Corp., Chief Executive Officer & Director at YM BioSciences, Inc., COO & Deputy Chief Executive Officer at Aventis Behring, Vice President of Allegiance Healthcare Corp. and President-Renal Division Europe at Baxter Healthcare Corp. She received an undergraduate degree from the University of California, Santa Cruz and an MBA from Stanford Graduate School of Business.
Carol M. Moore Presently, Carol M. Moore is Senior VP-Regulatory Affairs, Quality & Clinical at Cerus Corp. In the past Ms. Moore was Vice President-Worldwide Regulatory Affairs at Bayer Corp. She received an MBA from New York University and an undergraduate degree from The Cooper Union School of Engineering.
Timothy Bruce Anderson Timothy Bruce Anderson is on the board of Cerus Corp. and Lake Forest Hospital. In his past career he was Senior VP-Strategy & Business Development at Baxter International, Inc.
Kevin Dennis Green Kevin Dennis Green occupies the position of Chief Financial Officer & Vice President-Finance for Cerus Corp. In the past Mr. Green held the position of Finance Director & Assistant Controller at Macromedia, Inc. and Member of PricewaterhouseCoopers LLP.
Kevin Dennis Green Kevin Dennis Green occupies the position of Chief Financial Officer & Vice President-Finance for Cerus Corp. In the past Mr. Green held the position of Finance Director & Assistant Controller at Macromedia, Inc. and Member of PricewaterhouseCoopers LLP.
Vivek K. Jayaraman Vivek K. Jayaraman is Chief Commercial Officer for Cerus Corp. He previously occupied the position of Vice President-Commercial Operations at Trivascular2, Inc., Head-Media Relations, VP-Global Sales & Marketing at Trivascular Technologies, Inc., Vice President-Global Sales & Marketing at TriVascular, Inc. and Vice President-Global Marketing at Medtronic, Inc. He received an undergraduate degree from the University of Michigan and an MBA from The Wharton School of the University of Pennsylvania.
Suzanne Margerum Suzanne Margerum is Vice President-Development & Manufacturing at Cerus Corp. She previously occupied the position of Senior Corporate Counsel at Zynga, Inc. She received an undergraduate degree from The University of Chicago and an undergraduate degree from The University of Colorado Boulder.
Chrystal Menard Chrystal Menard holds the position of Chief Legal Officer & General Counsel at Cerus Corp. Ms. Menard previously occupied the position of Senior Corporate Counsel at Zynga, Inc. and Partner at Cooley LLP. Ms. Menard received a graduate degree from The University of Chicago and an undergraduate degree from The University of Colorado.
Nina Mufti Nina Mufti is Vice President-Development at Cerus Corp. She received a doctorate from Cornell University and an undergraduate degree from the University of Ottawa.
Nina Mufti Nina Mufti is Vice President-Development at Cerus Corp. She received a doctorate from Cornell University and an undergraduate degree from the University of Ottawa.
Timothy J. Lee Currently, Timothy J. Lee occupies the position of Director-Investor Relations of Cerus Corp.

量化对比

全部评论 3

  • 【疫苗股普遍下跌,血浆类股涨跌各异】疫苗股里,Alpha Pro Tech收跌将近5.5%,Vaxart跌约3.8%,诺瓦瓦克斯跌超2.5%,辉瑞制药跌约1.6%,阿斯利康跌超1.4%,Moderna跌超1.2%,Inovio Pharmaceuticals则涨超3.9%,辉瑞合作伙伴BioNTech也涨超6.0%。血浆类股里,Thermogenesis Holdings收跌逾10.6%,iBio跌超3.8%,T2 Biosystems跌超3%,Liminal BioSciences则涨约1.9%,Cerus也涨超1.7%。

  • 【疫苗股和血浆类股均普遍下跌】疫苗股Alpha Pro Tech跌超10%,诺瓦瓦克斯跌超9%,Inovio跌约6.0%,Moderna跌约2.3%,辉瑞制药跌约0.7%、其德国合作伙伴BioNTech也跌4.8%,阿斯利康则涨0.4%。血浆股iBio跌约10.6%,Thermogenesis跌约9.0%,Sonnet Biotherapeutics和Cancer Genetics均跌超6.5%,Liminal BioSciences和Cerus至少跌超5.6%。

  • 【疫苗股和血浆类股均普遍下跌】疫苗股Alpha Pro Tech跌超10%,诺瓦瓦克斯跌超9%,Inovio跌约6.0%,Moderna跌约2.3%,辉瑞制药跌约0.7%、其德国合作伙伴BioNTech也跌4.8%,阿斯利康则涨0.4%。血浆股iBio跌约10.6%,Thermogenesis跌约9.0%,Sonnet Biotherapeutics和Cancer Genetics均跌超6.5%,Liminal BioSciences和Cerus至少跌超5.6%。

阿布量化公众号二维码 abu_quant 扫一扫关注阿布量化

热门推荐